Autophagy-associated non-coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis.
Parkinson's disease
autophagy
ncRNA
neuroinflammation
α‐synuclein
Journal
CNS neuroscience & therapeutics
ISSN: 1755-5949
Titre abrégé: CNS Neurosci Ther
Pays: England
ID NLM: 101473265
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
revised:
18
04
2024
received:
19
02
2024
accepted:
28
04
2024
medline:
25
5
2024
pubmed:
25
5
2024
entrez:
25
5
2024
Statut:
ppublish
Résumé
Parkinson's disease (PD) is a degenerative neurological condition marked by the gradual loss of dopaminergic neurons in the substantia nigra pars compacta. The precise etiology of PD remains unclear, but emerging evidence suggests a significant role for disrupted autophagy-a crucial cellular process for maintaining protein and organelle integrity. This review focuses on the role of non-coding RNAs (ncRNAs) in modulating autophagy in PD. We conducted a comprehensive review of recent studies to explore how ncRNAs influence autophagy and contribute to PD pathophysiology. Special attention was given to the examination of ncRNAs' regulatory impacts in various PD models and patient samples. Findings reveal that ncRNAs are pivotal in regulating key processes associated with PD progression, including autophagy, α-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation. Dysregulation of specific ncRNAs appears to be closely linked to these pathogenic processes. ncRNAs hold significant therapeutic potential for addressing autophagy-related mechanisms in PD. The review highlights innovative therapeutic strategies targeting autophagy-related ncRNAs and discusses the challenges and prospective directions for developing ncRNA-based therapies in clinical practice. The insights from this study underline the importance of ncRNAs in the molecular landscape of PD and their potential in novel treatment approaches.
Sections du résumé
BACKGROUND
BACKGROUND
Parkinson's disease (PD) is a degenerative neurological condition marked by the gradual loss of dopaminergic neurons in the substantia nigra pars compacta. The precise etiology of PD remains unclear, but emerging evidence suggests a significant role for disrupted autophagy-a crucial cellular process for maintaining protein and organelle integrity.
METHODS
METHODS
This review focuses on the role of non-coding RNAs (ncRNAs) in modulating autophagy in PD. We conducted a comprehensive review of recent studies to explore how ncRNAs influence autophagy and contribute to PD pathophysiology. Special attention was given to the examination of ncRNAs' regulatory impacts in various PD models and patient samples.
RESULTS
RESULTS
Findings reveal that ncRNAs are pivotal in regulating key processes associated with PD progression, including autophagy, α-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation. Dysregulation of specific ncRNAs appears to be closely linked to these pathogenic processes.
CONCLUSION
CONCLUSIONS
ncRNAs hold significant therapeutic potential for addressing autophagy-related mechanisms in PD. The review highlights innovative therapeutic strategies targeting autophagy-related ncRNAs and discusses the challenges and prospective directions for developing ncRNA-based therapies in clinical practice. The insights from this study underline the importance of ncRNAs in the molecular landscape of PD and their potential in novel treatment approaches.
Substances chimiques
RNA, Untranslated
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14763Informations de copyright
© 2024 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.
Références
Frisardi V, Santamato A, Cheeran B. Parkinson's disease: new insights into pathophysiology and rehabilitative approaches. Parkinson's Dis. 2016;2016:3121727.
Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson's disease: recent advancement. Neurosci Bull. 2017;33(5):585‐597.
Surmeier DJ, Guzman JN, Sanchez‐Padilla J, Goldberg JA. What causes the death of dopaminergic neurons in Parkinson's disease? Prog Brain Res. 2010;183:59‐77.
Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A. Elevated tauopathy and alpha‐synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol. 2010;225(1):210‐218.
Lees AJ. L‐dopa treatment and Parkinson's disease. Q J Med. 1986;59(230):535‐547.
Müller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother. 2006;7(13):1715‐1730.
Boelens Keun JT, Arnoldussen IA, Vriend C, van de Rest O. Dietary approaches to improve efficacy and control side effects of levodopa therapy in Parkinson's disease: a systematic review. Adv Nutr. 2021;12(6):2265‐2287.
Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284‐2303.
Li W, Zhang H, Zhang Y, Wang K, Hui J, Yi Z. Comparison of the effectiveness, safety, and costs of anti‐Parkinson drugs: a multiple‐center retrospective study. CNS Neurosci Ther. 2023;30:e14531.
Bermejo Pareja F, Martinez‐Martin P, Muradas V, de Yébenes JG. Carbidopa dosage modifies L‐dopa induced side effects and blood levels of L‐dopa and other amino acids in advanced parkinsonism. Acta Neurol Scand. 1985;72(5):506‐511.
Perez CI, Kalyanasundar B, Moreno MG, Gutierrez R. The triple combination phentermine plus 5‐HTP/carbidopa leads to greater weight loss, with fewer psychomotor side effects than each drug alone. Front Pharmacol. 2019;10:1327.
Fu SC, Lee CH, Hsieh YC, Wu PH, Lin SH, Wang H. A pilot study exploring the association of Entacapone, gut microbiota, and the subsequent side effects in patients with Parkinson's disease. Front Cell Infect Microbiol. 2022;12:837019.
Wise A, Lemus HN, Fields M, Swan M, Bressman S. Refractory seizures secondary to vitamin B6 deficiency in Parkinson disease: the role of carbidopa‐levodopa. Case Rep Neurol. 2022;14(2):291‐295.
Nemet M, Andrijević A, Nedeljkov Đ, Andrić V, Gavrilović S. A case report on serotonin syndrome in a patient with Parkinson's disease: diagnostic and management challenges. Cureus. 2023;15(3):e36780.
Zhu JH, Guo F, Shelburne J, Watkins S, Chu CT. Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol. 2003;13(4):473‐481.
Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K. Alteration of autophagosomal proteins (LC3, GABARAP and GATE‐16) in Lewy body disease. Neurobiol Dis. 2011;43(3):690‐697.
Wang Y, Martinez‐Vicente M, Krüger U, et al. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet. 2009;18(21):4153‐4170.
Moors T, Paciotti S, Chiasserini D, et al. Lysosomal dysfunction and α‐Synuclein aggregation in Parkinson's disease: diagnostic links. Movement Disord. 2016;31(6):791‐801.
Bolam JP, Pissadaki EK. Living on the edge with too many mouths to feed: why dopamine neurons die. Movement Disord. 2012;27(12):1478‐1483.
Lv Q, Zhong Z, Hu B, et al. MicroRNA‐3473b regulates the expression of TREM2/ULK1 and inhibits autophagy in inflammatory pathogenesis of Parkinson disease. J Neurochem. 2021;157(3):599‐610.
Obergasteiger J, Frapporti G, Pramstaller PP, Hicks AA, Volta M. A new hypothesis for Parkinson's disease pathogenesis: GTPase‐p38 MAPK signaling and autophagy as convergence points of etiology and genomics. Mol Neurodegener. 2018;13(1):40.
Hussain MS, Afzal O, Gupta G, et al. Long non‐coding RNAs in lung cancer: unraveling the molecular modulators of MAPK signaling. Pathol Res Pract. 2023;249:154738.
Sarfraz M, Abida K, Eltaib L, et al. Overcoming chemoresistance and radio resistance in prostate cancer: the emergent role of non‐coding RNAs. Pathol Res Pract. 2024;255:155179.
Peng B, Li J, Yan Y, et al. Non‐coding RNAs: the recently accentuated molecules in the regulation of cell autophagy for ovarian cancer pathogenesis and therapeutic response. Front Pharmacol. 2023;14:1162045.
Ghafouri‐Fard S, Shoorei H, Mohaqiq M, Majidpoor J, Moosavi MA, Taheri M. Exploring the role of non‐coding RNAs in autophagy. Autophagy. 2022;18(5):949‐970.
Xu Z, Yan Y, Qian L, Gong Z. Long non‐coding RNAs act as regulators of cell autophagy in diseases (review). Oncol Rep. 2017;37(3):1359‐1366.
Wu J, Zhu Y, Cong Q, Xu Q. Non‐coding RNAs: role of miRNAs and lncRNAs in the regulation of autophagy in hepatocellular carcinoma (review). Oncol Rep. 2023;49(6):113.
Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441(7095):880‐884.
Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha‐Synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278(27):25009‐25013.
Cerri S, Blandini F. Role of autophagy in Parkinson's disease. Curr Med Chem. 2019;26(20):3702‐3718.
Chen LL, Huang YJ, Cui JT, Song N, Xie J. Iron dysregulation in Parkinson's disease: focused on the autophagy‐lysosome pathway. ACS Chem Nerosci. 2019;10(2):863‐871.
Pradas E, Martinez‐Vicente M. The consequences of GBA deficiency in the autophagy‐lysosome system in Parkinson's disease associated with GBA. Cells. 2023;12(1):191.
Oh CK, Dolatabadi N, Cieplak P, et al. S‐Nitrosylation of p62 inhibits Autophagic flux to promote α‐Synuclein secretion and spread in Parkinson's disease and Lewy body dementia. J Neurosci. 2022;42(14):3011‐3024.
Webb AE, Brunet A. FOXO transcription factors: key regulators of cellular quality control. Trends Biochem Sci. 2014;39(4):159‐169.
Audesse AJ, Dhakal S, Hassell LA, Gardell Z, Nemtsova Y, Webb AE. FOXO3 directly regulates an autophagy network to functionally regulate proteostasis in adult neural stem cells. PLoS Genet. 2019;15(4):e1008097.
Zhou J, Liao W, Yang J, et al. FOXO3 induces FOXO1‐dependent autophagy by activating the AKT1 signaling pathway. Autophagy. 2012;8(12):1712‐1723.
Dumitriu A, Latourelle JC, Hadzi TC, et al. Gene expression profiles in Parkinson disease prefrontal cortex implicate FOXO1 and genes under its transcriptional regulation. PLoS Genet. 2012;8(6):e1002794.
Zhang Y, James M, Middleton FA, Davis RL. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet. 2005;137b(1):5‐16.
Liu Y, Ao X, Ding W, et al. Critical role of FOXO3a in carcinogenesis. Mol Cancer. 2018;17(1):104.
Simunovic F, Yi M, Wang Y, et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain. 2009;132(Pt 7):1795‐1809.
Yan C, Liu J, Gao J, et al. IRE1 promotes neurodegeneration through autophagy‐dependent neuron death in the Drosophila model of Parkinson's disease. Cell Death Dis. 2019;10(11):800.
von Stockum S, Marchesan E, Ziviani E. Mitochondrial quality control beyond PINK1/Parkin. Oncotarget. 2018;9(16):12550‐12551.
Jimenez‐Moreno N, Lane JD. Autophagy and redox homeostasis in Parkinson's: a crucial balancing act. Oxid Med Cell Longev. 2020;2020:8865611.
Gao F, Yang J, Wang D, et al. Mitophagy in Parkinson's disease: pathogenic and therapeutic implications. Front Neurol. 2017;8:527.
Yang J, Zhang W, Zhang S, et al. Novel insight into functions of transcription factor EB (TFEB) in Alzheimer's disease and Parkinson's disease. Aging Dis. 2023;14(3):652‐669.
Atik A, Stewart T, Zhang J. Alpha‐Synuclein as a biomarker for Parkinson's disease. Brain Pathol. 2016;26(3):410‐418.
Moon HE, Paek SH. Mitochondrial dysfunction in Parkinson's disease. Exp Neurobiol. 2015;24(2):103‐116.
Gallegos S, Pacheco C, Peters C, Opazo CM, Aguayo LG. Features of alpha‐synuclein that could explain the progression and irreversibility of Parkinson's disease. Front Neurosci. 2015;9:59.
Grozdanov V, Danzer KM. Release and uptake of pathologic alpha‐synuclein. Cell Tissue Res. 2018;373(1):175‐182.
Brundin P, Dave KD, Kordower JH. Therapeutic approaches to target alpha‐synuclein pathology. Exp Neurol. 2017;298(Pt B):225‐235.
Emmenegger M, De Cecco E, Hruska‐Plochan M, et al. LAG3 is not expressed in human and murine neurons and does not modulate α‐synucleinopathies. EMBO Mol Med. 2021;13(9):e14745.
Gorecki AM, Anyaegbu CC, Anderton RS. TLR2 and TLR4 in Parkinson's disease pathogenesis: the environment takes a toll on the gut. Transl Neurodegener. 2021;10(1):47.
Nguyen LTN, Nguyen HD, Kim YJ, et al. Role of NLRP3 inflammasome in Parkinson's disease and therapeutic considerations. J Parkinsons Dis. 2022;12(7):2117‐2133.
Wu AG, Zhou XG, Qiao G, et al. Targeting microglial autophagic degradation in NLRP3 inflammasome‐mediated neurodegenerative diseases. Ageing Res Rev. 2021;65:101202.
Song JX, Lu JH, Liu LF, et al. HMGB1 is involved in autophagy inhibition caused by SNCA/α‐synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. Autophagy. 2014;10(1):144‐154.
Tu HY, Yuan BS, Hou XO, et al. α‐Synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson's disease. Aging Cell. 2021;20(12):e13522.
Hou X, Chen TH, Koga S, et al. Alpha‐synuclein‐associated changes in PINK1‐PRKN‐mediated mitophagy are disease context dependent. Brain Pathol. 2023;33(5):e13175.
Sarkar S, Olsen AL, Sygnecka K, Lohr KM, Feany MB. α‐Synuclein impairs autophagosome maturation through abnormal Actin stabilization. PLoS Genet. 2021;17(2):e1009359.
Tang Q, Gao P, Arzberger T, et al. Alpha‐Synuclein defects autophagy by impairing SNAP29‐mediated autophagosome‐lysosome fusion. Cell Death Dis. 2021;12(10):854.
Nascimento AC, Erustes AG, Reckziegel P, et al. α‐Synuclein overexpression induces lysosomal dysfunction and autophagy impairment in human neuroblastoma SH‐SY5Y. Neurochem Res. 2020;45(11):2749‐2761.
Oh C‐k, Nakamura T, Lipton SA. Inhibition of autophagic flux by S‐nitrosylation of SQSTM1/p62 promotes neuronal secretion and cell‐to‐cell transmission of SNCA/α‐synuclein in Parkinson disease and Lewy body dementia. Autophagy Rep. 2022;1(1):223‐225.
Brás IC, Xylaki M, Outeiro TF. Mechanisms of alpha‐synuclein toxicity: an update and outlook. Prog Brain Res. 2020;252:91‐129.
Sarkar S. Regulation of autophagy by mTOR‐dependent and mTOR‐independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. Biochem Soc Trans. 2013;41(5):1103‐1130.
Martinez‐Vicente M, Talloczy Z, Kaushik S, et al. Dopamine‐modified alpha‐synuclein blocks chaperone‐mediated autophagy. J Clin Invest. 2008;118(2):777‐788.
Paxinou E, Chen Q, Weisse M, et al. Induction of alpha‐synuclein aggregation by intracellular nitrative insult. J Neurosci. 2001;21(20):8053‐8061.
Klionsky DJ, Petroni G, Amaravadi RK, et al. Autophagy in major human diseases. EMBO J. 2021;40(19):e108863.
Winslow AR, Chen CW, Corrochano S, et al. α‐Synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol. 2010;190(6):1023‐1037.
Klucken J, Poehler AM, Ebrahimi‐Fakhari D, et al. Alpha‐synuclein aggregation involves a bafilomycin A 1‐sensitive autophagy pathway. Autophagy. 2012;8(5):754‐766.
Poehler AM, Xiang W, Spitzer P, et al. Autophagy modulates SNCA/α‐synuclein release, thereby generating a hostile microenvironment. Autophagy. 2014;10(12):2171‐2192.
Chavarría C, Ivagnes R, Souza JM. Extracellular alpha‐Synuclein: mechanisms for glial cell internalization and activation. Biomolecules. 2022;12(5):655.
Aflaki E, Stubblefield BK, McGlinchey RP, McMahon B, Ory DS, Sidransky E. A characterization of Gaucher iPS‐derived astrocytes: potential implications for Parkinson's disease. Neurobiol Dis. 2020;134:104647.
Tsunemi T, Ishiguro Y, Yoroisaka A, et al. Astrocytes protect human dopaminergic neurons from α‐Synuclein accumulation and propagation. J Neurosci. 2020;40(45):8618‐8628.
Sung K, Jimenez‐Sanchez M. Autophagy in astrocytes and its implications in neurodegeneration. J Mol Biol. 2020;432(8):2605‐2621.
Hussain MS, Gupta G, Afzal M, et al. Exploring the role of lncrna neat1 knockdown in regulating apoptosis across multiple cancer types: a review. Pathol Res Pract. 2023;252:154908.
Hussain MS, Altamimi ASA, Afzal M, et al. From carcinogenesis to therapeutic avenues: lncRNAs and mTOR crosstalk in lung cancer. Pathol Res Pract. 2024;253:155015.
Johnson JM, Edwards S, Shoemaker D, Schadt EE. Dark matter in the genome: evidence of widespread transcription detected by microarray tiling experiments. Trends in Genetics. 2005;21(2):93‐102.
Pennisi E. Shining a light on the genome's ‘dark matter’. Science. 2010;330(6011):1614.
Cech TR, Steitz JA. The noncoding RNA revolution‐trashing old rules to forge new ones. Cell. 2014;157(1):77‐94.
Lin D, Liang Y, Jing X, et al. Microarray analysis of an synthetic α‐synuclein induced cellular model reveals the expression profile of long non‐coding RNA in Parkinson's disease. Brain Res. 2018;1678:384‐396.
Cao B, Wang T, Qu Q, Kang T, Yang Q. Long noncoding RNA SNHG1 promotes neuroinflammation in Parkinson's disease via regulating miR‐7/NLRP3 pathway. Neuroscience. 2018;388:118‐127.
Zhang H, Yao L, Zheng Z, Koc S, Lu G. The role of non‐coding RNAs in the pathogenesis of Parkinson's disease: recent advancement. Pharmaceuticals. 2022;15(7):811.
Choi I, Woo JH, Jou I, Joe EH. PINK1 deficiency decreases expression levels of mir‐326, mir‐330, and mir‐3099 during brain development and neural stem cell differentiation. Exp Neurobiol. 2016;25(1):14‐23.
Zhao XH, Wang YB, Yang J, Liu HQ, Wang LL. MicroRNA‐326 suppresses iNOS expression and promotes autophagy of dopaminergic neurons through the JNK signaling by targeting XBP1 in a mouse model of Parkinson's disease. J Cell Biochem. 2019;120(9):14995‐15006.
Zhou L, Zhang Q, Deng H, Ou S, Liang T, Zhou J. The SNHG1‐centered ceRNA network regulates cell cycle and is a potential prognostic biomarker for hepatocellular carcinoma. Tohoku J Exp Med. 2022;258(4):265‐276.
Zhou X, Lu J, Wu B, Guo Z. HOXA11‐AS facilitates the proliferation, cell cycle process and migration of keloid fibroblasts through sponging miR‐188‐5p to regulate VEGFA. J Dermatol Sci. 2022;106(2):111‐118.
Sarkar A, Shamsuzzama KL, Hameed R, Nazir A. Multiple checkpoints of protein clearance machinery are modulated by a common microRNA, miR‐4813‐3p, through its putative target genes: studies employing transgenic C. elegans model. Biochim Biophys Acta Mol Cell Res. 2022;1869(12):119342.
Bai X, Dong Q, Zhao L, Yao Y, Wang B. microRNA‐106b‐containing extracellular vesicles affect autophagy of neurons by regulating CDKN2B in Parkinson's disease. Neurosci Lett. 2021;760:136094.
Liu L, Zhang Y, Tang L, et al. The neuroprotective effect of Byu d mar 25 in LPS‐induced Alzheimer's disease mice model. Evid Based Complement Alternat Med. 2021;2021:1‐12.
Sun S, Han X, Li X, et al. MicroRNA‐212‐5p prevents dopaminergic neuron death by inhibiting SIRT2 in MPTP‐induced mouse model of Parkinson's disease. Front Mol Neurosci. 2018;11:381.
Wang H, Ye Y, Zhu Z, et al. MiR‐124 regulates apoptosis and autophagy process in MPTP model of Parkinson's disease by targeting to Bim. Brain Pathol. 2016;26(2):167‐176.
Liu H, Li B, Xi P, et al. Time‐varying functional connectivity of rat brain during bipedal walking on unexpected terrain. Cyborg Bionic Syst. 2023;4:17.
Yao L, Zhu Z, Wu J, et al. MicroRNA‐124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson's disease. FASEB J. 2019;33(7):8648‐8665.
Chen J, Jiang C, Du J, Xie CL. MiR‐142‐5p protects against 6‐OHDA‐induced SH‐SY5Y cell injury by downregulating BECN1 and autophagy. Dose‐Response. 2020;18(1):1559325820907016.
Ba RQ, Liu J, Fan XJ, et al. Effects of miR‐199a on autophagy by targeting glycogen synthase kinase 3β to activate PTEN/AKT/mTOR signaling in an MPP(+) in vitro model of Parkinson's disease. Neurol Res. 2020;42(4):308‐318.
Zhang X, Li H, Wang H, et al. Iron/ROS/Itga3 mediated accelerated depletion of hippocampal neural stem cell pool contributes to cognitive impairment after hemorrhagic stroke. Redox Biol. 2024;71:103086.
Li W, Jiang Y, Wang Y, et al. MiR‐181b regulates autophagy in a model of Parkinson's disease by targeting the PTEN/Akt/mTOR signaling pathway. Neurosci Lett. 2018;675:83‐88.
Qin Y, Huang J, Zhao X, Chen C. MiR‐135a‐5p and Mst1 regulate MPP+‐1 induced apoptosis and autophagy in Parkinson's disease model in vitro. Cell Signal. 2022;94:110328.
Wen Z, Zhang J, Tang P, Tu N, Wang K, Wu G. Overexpression of miR‐185 inhibits autophagy and apoptosis of dopaminergic neurons by regulating the AMPK/mTOR signaling pathway in Parkinson's disease. Mol Med Rep. 2018;17(1):131‐137.
Zhang C, Ge H, Zhang S, et al. Hematoma evacuation via image‐guided para‐corticospinal tract approach in patients with spontaneous intracerebral hemorrhage. Neurol Ther. 2021;10:1001‐1013.
Liu Y, Song Y, Zhu X. MicroRNA‐181a regulates apoptosis and autophagy process in Parkinson's disease by inhibiting p38 mitogen‐activated protein kinase (MAPK)/c‐Jun N‐terminal kinases (JNK) signaling pathways. Med Sci Monitor. 2017;23:1597‐1606.
Wong AS, Lee RH, Cheung AY, et al. Cdk5‐mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's disease. Nat Cell Biol. 2011;13(5):568‐579.
Li G, Luo W, Wang B, et al. HMGA1 induction of miR‐103/107 forms a negative feedback loop to regulate autophagy in MPTP model of Parkinson's disease. Front Cell Neurosci. 2020;14:620020.
Li Q, Wang Z, Xing H, Wang Y, Guo Y. Exosomes derived from miR‐188‐3p‐modified adipose‐derived mesenchymal stem cells protect Parkinson's disease. Mol Ther Nucleic Acids. 2021;23:1334‐1344.
Wang R, Li Q, He Y, Yang Y, Ma Q, Li C. miR‐29c‐3p inhibits microglial NLRP3 inflammasome activation by targeting NFAT5 in Parkinson's disease. Genes Cells. 2020;25(6):364‐374.
Wang R, Yao J, Gong F, et al. miR‐29c‐3p regulates TET2 expression and inhibits autophagy process in Parkinson's disease models. Genes Cells. 2021;26(9):684‐697.
Li F, Li D, Liu H, et al. RNF216 regulates the migration of immortalized GnRH neurons by suppressing Beclin1‐mediated autophagy. Front Endocrinol. 2019;10:12.
Gong X, Wang H, Ye Y, et al. miR‐124 regulates cell apoptosis and autophagy in dopaminergic neurons and protects them by regulating AMPK/mTOR pathway in Parkinson's disease. Am J Transl Res. 2016;8(5):2127‐2137.
Dong X, He X, Yang L, Li Q, Xu Y. Inhibition of miR‐421 preserves mitochondrial function and protects against Parkinson's disease pathogenesis via Pink1/Parkin‐dependent mitophagy. Dis Markers. 2022;2022:5186252.
Zhu W, Zhang H, Gao J, Xu Y. Silencing of miR‐497‐5p inhibits cell apoptosis and promotes autophagy in Parkinson's disease by upregulation of FGF2. Environ Toxicol. 2021;36(11):2302‐2312.
Zhang C, Yu S, Zheng B, et al. miR‐30c‐5p reduces renal ischemia‐reperfusion involving macrophage. Med Sci Monitor. 2019;25:4362‐4369.
Zhou J, Zhao Y, Li Z, et al. miR‐103a‐3p regulates mitophagy in Parkinson's disease through Parkin/Ambra1 signaling. Pharmacol Res. 2020;160:105197.
Zhao J, Yang M, Li Q, Pei X, Zhu X. miR‐132‐5p regulates apoptosis and autophagy in MPTP model of Parkinson's disease by targeting ULK1. Neuroreport. 2020;31(13):959‐965.
Jauhari A, Singh T, Mishra S, Shankar J, Yadav S. Coordinated action of miR‐146a and Parkin gene regulate rotenone‐induced neurodegeneration. Toxicol Sci. 2020;176(2):433‐445.
Zhou T, Lin D, Chen Y, et al. α‐Synuclein accumulation in SH‐SY5Y cell impairs autophagy in microglia by exosomes overloading miR‐19a‐3p. Epigenomics. 2019;11(15):1661‐1677.
Chiu CC, Yeh TH, Chen RS, et al. Upregulated expression of MicroRNA‐204‐5p leads to the death of dopaminergic cells by targeting DYRK1A‐mediated apoptotic signaling Cascade. Front Cell Neurosci. 2019;13:399.
Shamsuzzama KL, Nazir A. Modulation of alpha‐synuclein expression and associated effects by MicroRNA Let‐7 in transgenic C. elegans. Front Mol Neurosci. 2017;10:328.
Kim J, Fiesel FC, Belmonte KC, et al. miR‐27a and miR‐27b regulate autophagic clearance of damaged mitochondria by targeting PTEN‐induced putative kinase 1 (PINK1). Mol Neurodegener. 2016;11(1):55.
Li G, Yang H, Zhu D, Huang H, Liu G, Lun P. Targeted suppression of chaperone‐mediated autophagy by miR‐320a promotes α‐synuclein aggregation. Int J Mol Sci. 2014;15(9):15845‐15857.
Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Björklund A. TFEB‐mediated autophagy rescues midbrain dopamine neurons from α‐synuclein toxicity. Proc Natl Acad Sci USA. 2013;110(19):E1817‐E1826.
Li J, Luo J, Liu L, Fu H, Tang L. The genetic association between apolipoprotein E gene polymorphism and Parkinson disease: a meta‐analysis of 47 studies. Medicine. 2018;97(43):e12884.
Lanford RE, Hildebrandt‐Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA‐122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962):198‐201.
Yeh C‐H, Zhang C, Shi W, Lo M‐T, Tinkhauser G, Oswal A. Cross‐frequency coupling and intelligent neuromodulation. Cyborg Bionic Syst. 2023;4:34.
Zhang L, Chen X, Chang M, Jiao B. MiR‐30c‐5p/ATG5 axis regulates the progression of Parkinson's disease. Front Cell Neurosci. 2021;15:644507.
Zhang HY, Wang ZG, Wu FZ, et al. Regulation of autophagy and ubiquitinated protein accumulation by bFGF promotes functional recovery and neural protection in a rat model of spinal cord injury. Mol Neurobiol. 2013;48(3):452‐464.
Bao M‐h, Luo H‐q, Chen L‐h, et al. Impact of high fat diet on long non‐coding RNAs and messenger RNAs expression in the aortas of ApoE (−/−) mice. Sci Rep. 2016;6(1):34161.
Shahab J, Maheshwari R, Singh M, et al. Cytomorphology of mesenchymal lesions in a tertiary care centre and its correlation with histopathology. CytoJournal. 2023;20:36.
Liu Z, Chen L, Cheng H, et al. Virtual formalin‐fixed and paraffin‐embedded staining of fresh brain tissue via stimulated Raman CycleGAN model. Sci Adv. 2024;10(13):eadn3426.
Jiang Z‐R, Yang L‐H, Jin L‐Z, et al. Identification of novel cuproptosis‐related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients. Front Oncol. 2022;12:988680.
Tang L, Wang Y, Xiang J, et al. lncRNA and circRNA expression profiles in the hippocampus of Aβ 25‐35‐induced AD mice treated with Tripterygium glycoside. Exp Ther Med. 2023;26(3):1‐14.
Li P, Zhong X, Li J, et al. MicroRNA‐30c‐5p inhibits NLRP3 inflammasome‐mediated endothelial cell pyroptosis through FOXO3 down‐regulation in atherosclerosis. Biochem Biophys Res Commun. 2018;503(4):2833‐2840.
Zhou L, Yang L, Li YJ, et al. MicroRNA‐128 protects dopamine neurons from apoptosis and upregulates the expression of excitatory amino acid transporter 4 in Parkinson's disease by binding to AXIN1. Cell Physiol Biochem. 2018;51(5):2275‐2289.
Shen Q‐q, Jv X‐h, Ma X‐z, et al. Cell senescence induced by toxic interaction between α‐synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson's disease. Acta Pharmacol Sin. 2024;45(2):268‐281.
Fan Y, Zhao X, Lu K, Cheng G. LncRNA BDNF‐AS promotes autophagy and apoptosis in MPTP‐induced Parkinson's disease via ablating microRNA‐125b‐5p. Brain Res Bull. 2020;157:119‐127.
Lang Y, Li Y, Yu H, et al. HOTAIR drives autophagy in midbrain dopaminergic neurons in the substantia nigra compacta in a mouse model of Parkinson's disease by elevating NPTX2 via miR‐221‐3p binding. Aging. 2020;12(9):7660‐7678.
Zhao Y, Xie Y, Yao WY, Wang YY, Song N. Long non‐coding RNA Opa interacting protein 5‐antisense RNA 1 promotes mitochondrial autophagy and protects SH‐SY5Y cells from 1‐methyl‐4‐phenylpyridine‐induced damage by binding to microRNA‐137 and upregulating NIX. Kaohsiung J Med Sci. 2022;38(3):207‐217.
Song Z, Xie B. LncRNA OIP5‐AS1 reduces α‐synuclein aggregation and toxicity by targeting miR‐126 to activate PLK2 in human neuroblastoma SH‐SY5Y cells. Neurosci Lett. 2021;740:135482.
Yan W, Chen ZY, Chen JQ, Chen HM. LncRNA NEAT1 promotes autophagy in MPTP‐induced Parkinson's disease through stabilizing PINK1 protein. Biochem Biophys Res Commun. 2018;496(4):1019‐1024.
Qian C, Ye Y, Mao H, et al. Downregulated lncRNA‐SNHG1 enhances autophagy and prevents cell death through the miR‐221/222 /p27/mTOR pathway in Parkinson's disease. Exp Cell Res. 2019;384(1):111614.
Kraus TFJ, Haider M, Spanner J, Steinmaurer M, Dietinger V, Kretzschmar HA. Altered long noncoding RNA expression precedes the course of Parkinson's disease‐a preliminary report. Mol Neurobiol. 2017;54(4):2869‐2877.
Fan Y, Li J, Yang Q, et al. Dysregulated long non‐coding RNAs in Parkinson's disease contribute to the apoptosis of human neuroblastoma cells. Front Neurosci. 2019;13:1320.
Chi LM, Wang LP, Jiao D. Identification of differentially expressed genes and long noncoding RNAs associated with Parkinson's disease. Parkinson's Dis. 2019;2019:6078251.
Liu Y, Lu Z. Long non‐coding RNA NEAT1 mediates the toxic of Parkinson's disease induced by MPTP/MPP+ via regulation of gene expression. Clin Exp Pharmacol Physiol. 2018;45(8):841‐848.
Zou J, Guo Y, Wei L, Yu F, Yu B, Xu A. Long noncoding RNA POU3F3 and α‐Synuclein in plasma L1CAM exosomes combined with β‐Glucocerebrosidase activity: potential predictors of Parkinson's disease. Neurotherapeutics. 2020;17(3):1104‐1119.
Bu LL, Xie YY, Lin DY, et al. LncRNA‐T199678 mitigates α‐synuclein‐induced dopaminergic neuron injury via miR‐101‐3p. Front Aging Neurosci. 2020;12:599246.
Huang H, Zheng S, Lu M. Downregulation of lncRNA MEG3 is involved in Parkinson's disease. Metab Brain Dis. 2021;36(8):2323‐2328.
Quan Y, Wang J, Wang S, Zhao J. Association of the plasma long non‐coding RNA MEG3 with Parkinson's disease. Front Neurol. 2020;11:532891.
Markowska A, Koziorowski D, Szlufik S. Microglia and stem cells for ischemic stroke treatment—mechanisms, current status, and therapeutic challenges. Front Biosci (Landmark Ed). 2023;28(10):269.
Dong LI, Zheng Y, Gao L, Luo X. lncRNA NEAT1 prompts autophagy and apoptosis in MPTP‐induced Parkinson's disease by impairing miR‐374c‐5p. Acta Biochim Biophys Sin. 2021;53(7):870‐882.
Alharbi KS, Almalki WH, Alzarea SI, et al. Anaesthesia‐induced changes in genomic expression leading to neurodegeneration. CNS Neurol Disord Drug Targets. 2024;23(4):411‐419.
Dong L, Zheng Y, Luo X. lncRNA NEAT1 promotes autophagy of neurons in mice by impairing miR‐107‐5p. Bioengineered. 2022;13(5):12261‐12274.
Zhao J, Li H, Chang N. LncRNA HOTAIR promotes MPP+‐induced neuronal injury in Parkinson's disease by regulating the miR‐874‐5p/ATG10 axis. EXCLI J. 2020;19:1141‐1153.
Almalki WH, Ghoneim MM, Alshehri S, Imam SS, Kazmi I, Gupta G. Sepsis triggered oxidative stress‐inflammatory axis: the pathobiology of reprogramming in the normal sleep‐wake cycle. Mol Cell Biochem. 2022;477(9):2203‐2211.
Safari MR, Komaki A, Arsang‐Jang S, Taheri M, Ghafouri‐Fard S. Expression pattern of long non‐coding RNAs in schizophrenic patients. Cell Mol Neurobiol. 2019;39(2):211‐221.
Hanan M, Simchovitz A, Yayon N, et al. A Parkinson's disease CircRNAs resource reveals a link between circSLC8A1 and oxidative stress. EMBO Mol Med. 2020;12(9):e11942.
Sang Q, Liu X, Wang L, et al. CircSNCA downregulation by pramipexole treatment mediates cell apoptosis and autophagy in Parkinson's disease by targeting miR‐7. Aging. 2018;10(6):1281‐1293.
Feng Z, Zhang L, Wang S, Hong Q. Circular RNA circDLGAP4 exerts neuroprotective effects via modulating miR‐134‐5p/CREB pathway in Parkinson's disease. Biochem Biophys Res Commun. 2020;522(2):388‐394.
Wang W, Lv R, Zhang J, Liu Y. circSAMD4A participates in the apoptosis and autophagy of dopaminergic neurons via the miR‐29c‐3p‐mediated AMPK/mTOR pathway in Parkinson's disease. Mol Med Rep. 2021;24(1):540.
Ravanidis S, Bougea A, Karampatsi D, et al. Differentially expressed circular RNAs in peripheral blood mononuclear cells of patients with Parkinson's disease. Movement Disord. 2021;36(5):1170‐1179.
Hussain MS, Altamimi ASA, Afzal M, et al. Kaempferol: paving the path for advanced treatments in aging‐related diseases. Exp Gerontol. 2024;188:112389.
McMillan KJ, Murray TK, Bengoa‐Vergniory N, et al. Loss of MicroRNA‐7 regulation leads to α‐Synuclein accumulation and dopaminergic neuronal loss in vivo. Mol Ther. 2017;25(10):2404‐2414.
Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384‐388.
Choi DC, Yoo M, Kabaria S, Junn E. MicroRNA‐7 facilitates the degradation of alpha‐synuclein and its aggregates by promoting autophagy. Neurosci Lett. 2018;678:118‐123.
Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. Repression of alpha‐synuclein expression and toxicity by microRNA‐7. Proc Natl Acad Sci USA. 2009;106(31):13052‐13057.
Shaikh MAJ, Altamimi ASA, Afzal M, et al. Unraveling the impact of miR‐21 on apoptosis regulation in glioblastoma. Pathol Res Pract. 2024;254:155121.
Ghosal S, Das S, Sen R, Basak P, Chakrabarti J. Circ2Traits: a comprehensive database for circular RNA potentially associated with disease and traits. Front Genet. 2013;4:283.
Guo JU, Agarwal V, Guo H, Bartel DP. Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 2014;15(7):409.
Kumar L, Shamsuzzama JP, Haque R, Shukla S, Nazir A. Functional characterization of novel Circular RNA molecule, circzip‐2 and its synthesizing gene zip‐2 in C. Elegans model of Parkinson's disease. Mol Neurobiol. 2018;55(8):6914‐6926.
Lukiw WJ. Circular RNA (circRNA) in Alzheimer's disease (AD). Front Genet. 2013;4:307.
Huang R, Zhang Y, Han B, et al. Circular RNA HIPK2 regulates astrocyte activation via cooperation of autophagy and ER stress by targeting MIR124‐2HG. Autophagy. 2017;13(10):1722‐1741.
Subramaniyan V, Fuloria S, Gupta G, et al. A review on epidermal growth factor receptor's role in breast and non‐small cell lung cancer. Chem Biol Interact. 2022;351:109735.
Policarpo R, Sierksma A, De Strooper B, d'Ydewalle C. From junk to function: LncRNAs in CNS health and disease. Front Mol Neurosci. 2021;14:714768.
Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673‐694.
Grafals‐Ruiz N, Rios‐Vicil CI, Lozada‐Delgado EL, et al. Brain targeted gold liposomes improve RNAi delivery for glioblastoma. Int J Nanomedicine. 2020;15:2809‐2828.
Thapa R, Afzal M, Goyal A, et al. Exploring ncRNA‐mediated regulation of EGFR signalling in glioblastoma: from mechanisms to therapeutics. Life Sci. 2024;345:122613.
Bernat V, Disney MD. RNA structures as mediators of neurological diseases and as drug targets. Neuron. 2015;87(1):28‐46.
Wu YY, Kuo HC. Functional roles and networks of non‐coding RNAs in the pathogenesis of neurodegenerative diseases. J Biomed Sci. 2020;27(1):49.
Matsui M, Corey DR. Non‐coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16(3):167‐179.
Nagatsua T, Sawadab M. L‐dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord. 2009;15(Suppl 1):S3‐S8.
Church FC. Treatment options for motor and non‐motor symptoms of Parkinson's disease. Biomolecules. 2021;11(4):612.
Bajan S, Hutvagner G. RNA‐based therapeutics: from antisense oligonucleotides to miRNAs. Cells. 2020;9(1):137.
Chakravarthy M, Chen S, Dodd PR, Veedu RN. Nucleic acid‐based theranostics for tackling Alzheimer's disease. Theranostics. 2017;7(16):3933‐3947.
Bennett CF, Krainer AR, Cleveland DW. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu Rev Neurosci. 2019;42:385‐406.
Riscado M, Baptista B, Sousa F. New RNA‐based breakthroughs in Alzheimer's disease diagnosis and therapeutics. Pharmaceutics. 2021;13(9):1397.
Sharma RK, Calderon C, Vivas‐Mejia PE. Targeting non‐coding RNA for glioblastoma therapy: the challenge of overcomes the blood‐brain barrier. Front Med Technol. 2021;3:678593.
Zhu Y, Zhu L, Wang X, Jin H. RNA‐based therapeutics: an overview and prospectus. Cell Death Dis. 2022;13(7):644.
Thapa R, Afzal O, Alfawaz Altamimi AS, et al. Galangin as an inflammatory response modulator: an updated overview and therapeutic potential. Chem Biol Interact. 2023;378:110482.
Burnett JC, Rossi JJ. RNA‐based therapeutics: current progress and future prospects. Chem Biol. 2012;19(1):60‐71.
Deng Y, Wang CC, Choy KW, et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene. 2014;538(2):217‐227.
Ho PY, Yu AM. Bioengineering of noncoding RNAs for research agents and therapeutics. Wiley Interdiscip Rev RNA. 2016;7(2):186‐197.
Beckert B, Masquida B. Synthesis of RNA by in vitro transcription. Methods Mol Biol. 2011;703:29‐41.
Khurana B, Goyal AK, Budhiraja A, Aora D, Vyas SP. Lipoplexes versus nanoparticles: pDNA/siRNA delivery. Drug Deliv. 2013;20(2):57‐64.
Pereira P, Queiroz JA, Figueiras A, Sousa F. Current progress on microRNAs‐based therapeutics in neurodegenerative diseases. Wiley Interdiscip Rev RNA. 2017;8(3). doi:10.1002/wrna.1409
Zenaro E, Piacentino G, Constantin G. The blood‐brain barrier in Alzheimer's disease. Neurobiol Dis. 2017;107:41‐56.
Profaci CP, Munji RN, Pulido RS, Daneman R. The blood–brain barrier in health and disease: important unanswered questions. J Exp Med. 2020;217(4):e20190062.
Pardridge WM. Blood–brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci. 2019;11:373.
Pardridge WM. Blood–brain barrier delivery of protein and non‐viral gene therapeutics with molecular Trojan horses. J Control Release. 2007;122(3):345‐348.
Wu L, Xu Q, Zhou M, et al. Plasma miR‐153 and miR‐223 levels as potential biomarkers in Parkinson's disease. Front Neurosci. 2022;16:865139.
Ma Z, Liang H, Hu B, Cai S, Yan D. Autophagy‐regulating miRNAs: novel therapeutic targets for Parkinson's disease (review). Int J Mol Med. 2023;51(6):50.
Liao J, Zhang Q, Huang J, et al. The emerging role of circular RNAs in Parkinson's disease. Front Neurosci. 2023;17:1137363.
Watson CN, Belli A, Di Pietro V. Small non‐coding RNAs: new class of biomarkers and potential therapeutic targets in neurodegenerative disease. Front Genet. 2019;10:364.
Liu S, Cui B, Dai ZX, Shi PK, Wang ZH, Guo YY. Long non‐coding RNA HOTAIR promotes Parkinson's disease induced by MPTP through up‐regulating the expression of LRRK2. Curr Neurovasc Res. 2016;13(2):115‐120.
Shah AM, Giacca M. Small non‐coding RNA therapeutics for cardiovascular disease. Eur Heart J. 2022;43(43):4548‐4561.
Kara G, Arun B, Calin GA, Ozpolat B. miRacle of microRNA‐driven cancer Nanotherapeutics. Cancer. 2022;14(15):3818.
Acharya S, Lumley AI, Devaux Y. Non‐coding RNAs and stem cells: the dream team for neural regeneration in Parkinson's disease? Neural Regen Res. 2021;16(10):2017‐2018.
Li X, Qi H, Cui W, et al. Recent advances in targeted delivery of non‐coding RNA‐based therapeutics for atherosclerosis. Mol Ther. 2022;30(10):3118‐3132.
Acharya S, Salgado‐Somoza A, Stefanizzi FM, et al. Non‐coding RNAs in the brain‐heart Axis: the case of Parkinson's disease. Int J Mol Sci. 2020;21(18):6513.
Ito M, Miyata Y, Okada M. Current clinical trials with non‐coding RNA‐based therapeutics in malignant diseases: a systematic review. Translat Oncol. 2023;31:101634.